Data / Form D filings / Evogen, Inc.
Evogen, Inc.: Form D filings
Evogen, Inc., a biotechnology company in Lenexa, KS, filed 2 Form D notices with the SEC between 2010 and 2014. The latest, on February 19, 2014, reports $852,420 sold of a $1.6 million offering to 8 investors.
Find out what Evogen, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 10513 W. 84th Terrace, Lenexa, KS, 64214
- Phone
- (913) 312-5676
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1170875
The full lists. Form D filings in Kansas: 193 rows, $9.65, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 19, 2014 | New notice | $1,580,000 | $852,420 | $727,580 | 8 | Jan 21, 2014 | sec.gov |
| Jan 25, 2010 | New notice | $2,000,000 | $1,041,322 | $958,678 | 10 | Jan 11, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Nathan Ledeboer | Director | |
| Hans Kastensmith | Executive Officer, Director, Promoter | |
| Richard St. Clair | Executive Officer | |
| Jonathan Leitersdorf | Director | |
| Robert Dondes | Executive Officer | |
| Sean Reineke | Director |
Every Form D from the week of Feb 17, 2014 · All recent filings in Kansas · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Evogen, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.